These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 18788619

  • 1. [Study of fibrinolysis inhibitors in 117 acute leukemia patients].
    Wang W, Ji CY, Ye JJ, Zhu YY, Guo DM, Ji M.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):183-6. PubMed ID: 18788619
    [Abstract] [Full Text] [Related]

  • 2. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 3. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [Abstract] [Full Text] [Related]

  • 4. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D.
    Thromb Res; 2006 Sep; 118(4):495-500. PubMed ID: 16318869
    [Abstract] [Full Text] [Related]

  • 5. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 6. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 7. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL, Graham C, Harding SA, Ludlam CA, Fox KA, Newby DE.
    Thromb Res; 2006 Sep; 118(2):189-97. PubMed ID: 16055173
    [Abstract] [Full Text] [Related]

  • 8. TAFI and PAI-1 levels in human sepsis.
    Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA.
    Thromb Res; 2006 Sep; 118(2):205-12. PubMed ID: 16009400
    [Abstract] [Full Text] [Related]

  • 9. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [Abstract] [Full Text] [Related]

  • 10. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
    Agren A, Wiman B, Schulman S.
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
    [Abstract] [Full Text] [Related]

  • 11. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
    Ricart JM, Ramón LA, Vayá A, España F, Santaolaria ML, Todolí J, Castelló R, Fontcuberta J, Estellés A.
    Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
    [Abstract] [Full Text] [Related]

  • 12. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
    Ozeren M, Karahan SC, Ozgur M, Eminagaoglu S, Unsal M, Baytan S, Bozkaya H.
    Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
    [Abstract] [Full Text] [Related]

  • 13. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.
    Med Princ Pract; 2009 Oct; 18(4):266-71. PubMed ID: 19494532
    [Abstract] [Full Text] [Related]

  • 14. Thrombin activatable fibrinolysis inhibitor (TAFI) in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG).
    Lisowski P, Małyszko J, Hirnle T, Lisowska A, Jackowski R, Małyszko JS, Buzun L, Myśliwiec M.
    Rocz Akad Med Bialymst; 2005 Oct; 50():166-72. PubMed ID: 16358959
    [Abstract] [Full Text] [Related]

  • 15. Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever.
    Sonmez M, Aydin K, Durmus A, Sucu N, Yilmaz M, Akdogan E, Koksal I, Ovali E, Omay SB.
    J Infect; 2007 Aug; 55(2):184-7. PubMed ID: 17418898
    [Abstract] [Full Text] [Related]

  • 16. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
    Kemona-Chetnik I, Kowal K, Kucharewicz I, Pampuch A, Bodzenta-Lukaszyk A.
    Przegl Lek; 2006 Aug; 63(12):1281-5. PubMed ID: 17642140
    [Abstract] [Full Text] [Related]

  • 17. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R.
    Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
    [Abstract] [Full Text] [Related]

  • 18. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW, Wang LL, Wu XB, Zhao JJ, Du YM, Jiang CY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
    [Abstract] [Full Text] [Related]

  • 19. Quantification of the effects of thrombin activatable fibrinolysis inhibitor and alpha2-antiplasmin on fibrinolysis in normal human plasma.
    Nielsen VG, Ellis TC.
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):29-33. PubMed ID: 17179823
    [Abstract] [Full Text] [Related]

  • 20. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
    Akinci B, Demir T, Saygili S, Yener S, Alacacioglu I, Saygili F, Bayraktar F, Yesil S.
    Diabetes Res Clin Pract; 2008 Jul; 81(1):93-6. PubMed ID: 18406001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.